Figg WD - Search Results

1

DPYD Testing: Time to Put Patient Safety First.

Baker SD, Bates SE, Brooks GA, Dahut WL, Diasio RB, El-Deiry WS, Evans WE, Figg WD, Hertz DL, Hicks JK, Kamath S, Kasi PM, Knepper TC, McLeod HL, O'Donnell PH, Relling MV, Rudek MA, Sissung TM, Smith DM, Sparreboom A, Swain SM, Walko CM. Baker SD, et al. Among authors: figg wd. J Clin Oncol. 2023 May 20;41(15):2701-2705. doi: 10.1200/JCO.22.02364. Epub 2023 Feb 23. J Clin Oncol. 2023. PMID: 36821823 Free PMC article. No abstract available.

2

Initial pharmacokinetics and bioavailability of PSC 833, a P-glycoprotein antagonist.

Lush RM, Meadows B, Fojo AT, Kalafsky G, Smith HT, Bates S, Figg WD. Lush RM, et al. Among authors: figg wd. J Clin Pharmacol. 1997 Feb;37(2):123-8. doi: 10.1002/j.1552-4604.1997.tb04770.x. J Clin Pharmacol. 1997. PMID: 9055138 Clinical Trial.

3

Taxanes in hormone-refractory prostate cancer.

Kang MH, Figg WD, Dahut W. Kang MH, et al. Among authors: figg wd. Cancer Pract. 1999 Sep-Oct;7(5):270-2. doi: 10.1046/j.1523-5394.1999.75005.x. Cancer Pract. 1999. PMID: 10687598 Review. No abstract available.

4

High-performance liquid chromatography with mass spectrometry detection for quantitating COL-3, a chemically modified tetracycline, in human plasma.

Rudek MA, March CL, Bauer KS Jr, Pluda JM, Figg WD. Rudek MA, et al. Among authors: figg wd. J Pharm Biomed Anal. 2000 Jul;22(6):1003-14. doi: 10.1016/s0731-7085(00)00257-0. J Pharm Biomed Anal. 2000. PMID: 10857569

5

A high-performance liquid chromatography method using ultraviolet and fluorescence detection for the quantitation of UCN-01, 7-hydroxystaurosporine, from human plasma and saliva.

Bauer KS, Lush RM, Rudek MA, Shih C, Sausville E, Figg WD. Bauer KS, et al. Among authors: figg wd. Biomed Chromatogr. 2000 Aug;14(5):338-43. doi: 10.1002/1099-0801(200008)14:5<338::AID-BMC993>3.0.CO;2-6. Biomed Chromatogr. 2000. PMID: 10960835

6

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

Chico I, Kang MH, Bergan R, Abraham J, Bakke S, Meadows B, Rutt A, Robey R, Choyke P, Merino M, Goldspiel B, Smith T, Steinberg S, Figg WD, Fojo T, Bates S. Chico I, et al. Among authors: figg wd. J Clin Oncol. 2001 Feb 1;19(3):832-42. doi: 10.1200/JCO.2001.19.3.832. J Clin Oncol. 2001. PMID: 11157037 Clinical Trial.

7

Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.

Rudek MA, Figg WD, Dyer V, Dahut W, Turner ML, Steinberg SM, Liewehr DJ, Kohler DR, Pluda JM, Reed E. Rudek MA, et al. Among authors: figg wd. J Clin Oncol. 2001 Jan 15;19(2):584-92. doi: 10.1200/JCO.2001.19.2.584. J Clin Oncol. 2001. PMID: 11208854 Clinical Trial.

8

Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.

Rudek MA, Horne M, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Rudek MA, et al. Among authors: figg wd. Am J Hematol. 2001 May;67(1):51-3. doi: 10.1002/ajh.1076. Am J Hematol. 2001. PMID: 11279658 Free article.

9

Drug-induced lupus associated with COL-3: report of 3 cases.

Ghate JV, Turner ML, Rudek MA, Figg WD, Dahut W, Dyer V, Pluda JM, Reed E. Ghate JV, et al. Among authors: figg wd. Arch Dermatol. 2001 Apr;137(4):471-4. Arch Dermatol. 2001. PMID: 11295928 Clinical Trial.

10

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

Kang MH, Figg WD, Ando Y, Blagosklonny MV, Liewehr D, Fojo T, Bates SE. Kang MH, et al. Among authors: figg wd. Clin Cancer Res. 2001 Jun;7(6):1610-7. Clin Cancer Res. 2001. PMID: 11410497 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

774 results

Search Page